Summary

Although the morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with coronary artery disease and left ventricULar dysfunction [BEAUTIFUL; NCT00143507] trial failed to meet its primary composite endpoint of cardiovascular death, admission to hospital for acute myocardial infarction (MI), and hospitalization for new-onset or worsening heart failure, it significantly reduced important secondary endpoints, such as hospitalization for fatal or non-fatal MI and coronary revascularization.